Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zhejiang Wansheng Pharmaceutical Co. Ltd.

Division of 3SBio Inc.

Latest From Zhejiang Wansheng Pharmaceutical Co. Ltd.

3SBio Acquires Wansheng To Bolster Small Molecule Portfolio

China’s 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • 3SBio Inc.
  • Senior Management
  • Luo Xie Long, CEO
  • Contact Info
  • Zhejiang Wansheng Pharmaceutical Co. Ltd.
    Phone: 571 88270801
    10F Bldg. D
    380# Fengtan Rd